Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said, "Successful launch of Famotidine is a demonstration of Vivimed's COMO capability to prestigious Canada market in collaboration with a highly respected strategic partner. This sets the stage for exciting new range of COMO products. In the next 6 months, Vivimed shall continue to leverage end to end capabilities to expand its COMO footprint."
Famotidine tablets are used for relief of heartburn, indigestion, upset stomach, sour stomach due to excess stomach acid, hyperacidity and/or acid indigestion and (2) for the prevention of the symptoms of excess stomach acid brought on by consuming food and/or beverages which may cause symptoms.
On Sensex, Vivimed closed at the upper circuit of Rs29.70 per piece higher by 4.95%.